• Cultivation becoming a commodity

• Value added products substituting flowers

• Growing emphasis on proven medical efficacy

• Opening of international markets

• New entrants from pharma and FMCG

• Low cost and scale

• Product innovation

• R&D and intellectual property

• Exports and multi-domestic supply chains

• Branding

• Downstream focus with limited in-house grow, and ability to source flower at 0.10$/gr vs Canada 2.00$

• Strong product pipeline supported by strategic innovation alliances

• Medical IP sourced from US, Canada and Israeli R&D providers

• Local distribution offices in key markets

• Adult use brands exposed to 40 M Las Vegas tourists